Dengue Virus Induces NK Cell Activation through TRAIL Expression during Infection

Mariana Gandini,1,2 Fabienne Petitinga-Paiva,1 Cintia Ferreira Marinho,1 Gladys Correa,1 Luzia Maria De Oliveira-Pinto,1 Luiz José de Souza,3 Rivaldo Venâncio Cunha,4 Claire Fernandes Kubelka,1 and Elzinandes Leal de Azeredo1

1Viral Immunology Laboratory, Oswaldo Cruz Institute/FIOCRUZ, Rio de Janeiro, RJ, Brazil
2Celular Microbiology Laboratory, Oswaldo Cruz Institute/FIOCRUZ, Rio de Janeiro, RJ, Brazil
3Plantadores de Cana Hospital, Campos dos Goytacazes, RJ, Brazil
4Medical Clinic Department, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil

Correspondence should be addressed to Elzinandes Leal de Azeredo; elzinandes@ioc.fiocruz.br

Received 15 February 2017; Revised 29 June 2017; Accepted 9 July 2017; Published 5 September 2017

Copyright © 2017 Mariana Gandini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dengue is an acute febrile illness with a wide spectrum of signs and symptoms ranging from mild to severe forms characterized by plasma leakage that can be fatal. NK cells are one of the main effectors in early infection and may play an important role in dengue pathogenesis. We investigated NK cell involvement during dengue infection. A higher frequency of NK cell subsets and TRAIL+NK cells was found in mild DF cases when compared to that in severe cases or healthy donors. NK activation markers such as CD107a and TLR3 were upregulated in patients’ cells compared to those in healthy donors. In addition, IL12 related to NK cell activation were upregulated in mild DF cases. In vitro PBMC culture models show that DENV-stimulated and IFNα-stimulated NK cells were able to express TRAIL, suggesting an indirect activation of cells, regarding TRAIL expression. Type I IFN receptor blockage on DENV-stimulated PBMCs showed TRAIL expression on NK cells is partially IFNα dependent. In addition, during PBMC stimulation, TRAIL expression on NK cells was inversely correlated with DENV-positive monocytes. Therefore, we observed DENV-induced activation of NK cell populations. A higher activation of NK cells would promote limited viral spread, resulting in decreased inflammatory response, contributing to protection against dengue severity.

1. Introduction

Dengue fever is an arboviral disease endemic at tropical and subtropical regions where 2.5 billion people are at risk. No vaccine or specific treatments are currently licensed or available. Dengue is a major health problem in Brazil, responding to the majority of cases in the Americas. Dengue virus (DENV) is a flavivirus, and all serotypes (DENV-1 to 4) may cause disease in which hemorrhagic manifestations and/or effusions may lead to severe clinical forms [1]. The wide range of observed clinical forms may reflect a synergism of several causes such as host genetic factors [2–4], cross-reactive cellular and antibody responses [5, 6], and/or strain virulence [7]. However, the majority of dengue patients present only mild symptoms and recover after defervescence. Immune response to DENV may play a role in pathophysiology, in which high levels of cytokines were correlated to severity [8]. Soluble mediators released in consequence of viral infection may promote endothelial activation and, subsequently, a systemic short-term plasma leakage [1]. Besides, DENV replication may subvert innate immunity mechanisms, specially type I interferon signaling [9], suggesting a negative impact in innate immune antiviral responses.

NK cells are key players during initial viral infection, mainly acting on delaying viral spread through cytotoxicity towards infected cells. NK cells are activated by type I interferons that increase cytotoxicity against infected cells and promote immunoregulatory functions through cytokine
release [10]. NK cells become activated as a result of signals received from target cells, in which the integration of signaling between NK cell membrane-bound activating or inhibitory receptors and membrane-bound ligands on infected cells dictates survival or death; activation can also indirectly result from cytokine signaling or pathogen recognition itself [11]. Effective cytotoxicity is mediated by classical degranulation, but also by expression of surface death molecules Fas (CD95/APO-1) and TRAIL (tumor necrosis factor- (TNF-) related apoptosis inducing) [12, 13]. TRAIL is a transmembrane or soluble protein of the TNF superfamily with apoptosis-inducing functions mediated by binding to its death receptors TRAIL-R1/-R2 on target cells [14, 15]. TRAIL expression on NK cells can be induced by type I interferons, we questioned whether NK function during dengue disease needs further elucidation. Considering that TRAIL expression on NK cells can be induced by type I interferons, we questioned whether NK cells could express TRAIL during dengue infection.

2. Material and Methods

2.1. Human Blood Samples. Blood from 43 dengue patients with confirmed dengue fever from two Brazilian health centers located at Campo Grande state of Mato Grosso do Sul and Campos dos Goytacazes, state of Rio de Janeiro, was analyzed. Diagnosis of dengue cases was performed using Dengue Virus IgM Capture DxSelect™ (Focus Diagnostics, California, USA) and Platelia™ Dengue NS1 Ag ELISA (Bio-Rad Laboratories, California, USA). Molecular detection and serotype typing were performed as described previously [19]. All experimental procedures with human blood were approved by the ethical committee at Plataforma Brasil, Fiocruz (CAAE 13318113.7.0000.5248). All patients were informed of the procedures and gave written consent. Demographic information about the studied population as well as the classification criteria is described in Table 1.

Table 1: Demographic, clinical, and laboratorial characteristics of DENV infected patients.

| Characteristics                  | DF & DFWS | (N)  | Severe dengue | (N)  |
|----------------------------------|-----------|------|---------------|------|
| Age (median, 25–75%)             | 43, 26–58 | (33) | 42, 24–50     | (10) |
| Gender (M:F)                     | 14 : 19   | (31) | 5 : 5         | (10) |
| Infecting serotype               |           |      |               |      |
| DENV-2 positive/tested%          | 9/33 (27.2%) | (33) | 1/10 (10.0%)  | (10) |
| DENV-1 positive/tested%          | 4/33 (12.1%) | (33) | 0/10 (0%)     | (10) |
| Previous dengue infection (IgG positive) | 79% | (30) | 100%         | (8)  |
| Platelet count (×10³/mm³)        | 121 (82–146.8) | (23) | 28 (2.5–77.4) | +5  |
| Hematocrit                       | 42 (39.8–43.6) | (22) | 43 (38.4–47)  | (7)  |
| Leucocyte count (×10³/mm³)       | 4500 (3442–6218) | (27) | 2750 (1737–4270) | (8)  |
| ALT (IU/L)                       | 63 (47.6–140.1) | (23) | 159 (54–583) | +5  |
| AST (IU/L)                       | 74.5 (56.8–132) | (23) | 145 (115.7–667.7) | +δ |

Study population n = 43; DF (dengue fever without warning signs) and DFWS (dengue fever with warning signs; severe dengue according to [21]); number of patients with available data; CI, 95% confidence interval; *p < 0.05 represents statistical difference of DF and DFWS versus severe dengue; Mann–Whitney nonparametric test was applied; $p = 0.0945.

2.2. Human Cell Isolation and Stimulation. Cryopreserved peripheral blood mononuclear cells (PBMC) from patients/healthy donors or fresh PBMC from healthy donors were obtained from density gradient centrifugation of either heparinized blood or buffy coats, respectively, with a Ficoll-Hyphaque separation medium (GE Healthcare). In vitro experiments were performed with fresh PBMC from healthy donors. Cells were cultured in RPMI 1640 (Invitrogen, Gaithersburg, MD, USA) containing 10% fetal bovine serum (HyClone) and 1% penicillin-streptomycin-glutamine (Gibco) at 37°C in a humidified 5% CO2 chamber according to the protocol. Dengue virus type 2 strain Thailand/16681/1984 (DENV-2) [20] was used for viral stimulation. Viral stock preparation and titration are described elsewhere [17]. Uninfected C6/36 cell supernatant was purified and used as negative control (MOCK). PBMCs at 2 × 10⁶ cells/1.0 mL were cultured overnight with DENV-2 (MOIs 0.1, 1, or 10), 150 ng/mL of soluble recombinant IFNa (PBL International), MOCK, or unstimulated. When required, monoclonal anti-human IFNAR2 (PBL International) at 1.5 μg/mL per well was added 60 min prior to subsequent stimulation.

2.3. Flow Cytometry and ELISA. Ex vivo PBMCs were immediately thawed, washed in cold wash buffer (phosphate-buffered saline, 2% fetal bovine serum, and 1 mM ethylenediamine tetraacetic acid). Cells were blocked with wash buffer containing 5% of heat-inactivated human plasma, followed by staining with CD16-FITC (SouthernBio-tech), TRAIL-PE or isotype-matched antibody (BD Biosciences), CD3– Pacific Blue (BioLegend), CD107a-eFluor660 or isotype-matched antibody, and CD56-PeCy5.5 (eBioscience), and fixed with 2% paraformaldehyde prior to analysis. Cell cultures were stained with the same antibodies as patients'
2.4. Statistical Analysis. In vitro experiments were repeated at least four times. p values (p) were determined using a two-tailed Wilcoxon matched pair test for paired in vitro data and nonparametric Mann–Whitney test for patient data (Prism 6.0, GraphPad). p < 0.05 was considered statistically significant. Values were submitted to one-way analyses of variance to test for linear trend in which p < 0.05 was statistically significant.

3. Results

3.1. NK Cells Display Increased Frequency in Mild Dengue Patients. The patients enrolled in the study presented fever accompanied by one or more of the following symptoms: myalgia, arthralgia, exanthema, headache, prostration, pruritus, conjunctival hyperemia, edema, nausea, vomiting, and retro orbital pain. Dengue-infected patients were classified according to the latest WHO classification [21]. Of these, 28 were classified as DF without warning signs, 5 as DF with warning signs, and 10 as severe dengue. There were no significant statistical differences in age, sex, fever, or other symptoms between groups of patients analyzed. However, severe patients presented lower platelet counts and higher ALT levels as compared with DF without warning signs/DF with warning signs. Severe cases had a higher frequency of persistent abdominal pain, followed by uncontrollable vomiting and strokes (pericardial or pleural or ascites). Demographic and laboratorial information are summarized in Table 1.

NK cells exert their function during viral infection mainly by cytotoxicity towards infected cells and through cytokine production [22]. Because CD16+ NK cells are considered highly cytotoxic and CD16− NK cells feature enhanced cytokine production, we analyzed the frequencies of CD56+CD16− and CD56+CD16+ subsets among NK cells during acute dengue disease (Figure 1). Both subsets show frequencies among PBMCs greater in dengue fever patients (DF) than those from NK cells of healthy donors (HD) or severe dengue (SD) cases. Patients presenting warning signs (DFWS) displayed intermediate percentages of both NK cell subsets, suggesting an association between NK cell circulating frequencies and disease severity. Indeed, we observed a negative linear trend towards severity when CD56+CD16− NK cells are analyzed (linear trend: slope −2.41, r² 0.1215, p = 0.0299). Therefore, dengue infection has a positive impact on NK cell population.

3.2. Dengue Patients’ NK Cells Display Activation Features: CD107α and TLR3 Expression Are Upregulated and TRAIL Is Increased in Mild Patients. To study NK cell activation/cytotoxic profile during dengue infection, apoptotic inducer TRAIL, membrane degranulation marker CD107α [23], and pattern recognition TLR3 were assessed in patients’ CD3−CD56+CD16+ NK cells. Because frequencies of CD16− NK cells were low, we elected only CD16+ NK cells for that analysis, as gated in Figure 2(a).

TRAIL+ NK cell frequency and TRAIL MFI on NK cells were significantly higher in PBMC during acute dengue fever as compared to those in healthy donors (Figure 2(b)), as well as CD107α expression (Figure 2(c)) and TLR3-positive NK cells (Figure 2(d)). Remarkably, TRAIL+ NK cell frequency was significantly greater in PBMC of mild cases of dengue (DF) as compared to that in severe cases (SD) (Figure 2(b)):
However, the same was not observed for TRAIL MFI analysis in the same population. Moreover, a significant negative linear trend towards severity was observed considering TRAIL-positive cells on CD3−CD56+CD16+ NK cells from patients (linear trend: slope $-12.83$, $r^2 = 0.2016$, $p = 0.0359$). We observed no difference in CD107a expression or TLR3-positive cells between disease groups studied.

Circulating cytokines may promote NK cell activation and therefore were analyzed in plasma samples of those patients. Previous work from our group described a significantly enhanced production of IFNγ and soluble TRAIL in plasma samples from the same patient group analyzed in this work [17] and was significantly more pronounced in mild patients as compared to that in severe ones. IL12 can both promote IFNγ production and TRAIL expression by NK cells [24, 25]. When soluble IL12 was analyzed in plasma samples, significant higher levels were found in mild dengue (DF) patients (median 122 pg/mL, $n = 11$, $p = 0.006$) as compared to that in healthy donors (median 63 pg/mL, $n = 9$) and a negative trend toward severity was observed (Figure 2(e)). Taken together, we observed that the degree of NK cell activation may have a role in disease progression.

### 3.3. NK Cells Express Membrane TRAIL after In Vitro DENV Stimulation

In order to understand TRAIL expression on NK cells during DENV infection, we investigated whether...
in vitro DENV stimulation could enhance membrane TRAIL detection on NK cells. Both CD3−CD56+CD16− and CD3−CD56+CD16+ NK cell subsets were analyzed (Figure 3(a)). Overnight stimulation of the healthy donors’ PBMCs with DENV-2 significantly impacted on CD16− NK cell frequency as compared to mock infection or unstimulated cells (n = 12, p < 0.05). No differences were detected for CD16+ NK cell frequency after DENV stimulation. Membrane TRAIL expression was observed NK cells in both subsets as compared to mock-treated or unstimulated NK cells (Figure 3(c)). TRAIL detection was DENV-2 dose dependent on both subsets of NK cells analyzed as evidenced by a decreased TRAIL detection when lower MOIs were tested (Figure 3(c)). Remarkably, CD3−CD56+CD16− NK cells exhibit more TRAIL+ cells than CD16+ subpopulation once compared at higher DENV-2 MOIs (n = 12, p < 0.05).

Therefore, we observed that dengue infection is able to induce TRAIL expression on NK cells during both ex vivo and in vitro studies.

3.4. Type I Interferons Are Involved in TRAIL Expression on NK Cells during DENV-2 Stimulation. Considering that type I interferons mediate TRAIL expression on NK cells [12], we next sought to study a role for those cytokines during in vitro stimulation. Firstly, we observed that IFNα was detected in the supernatant only during DENV stimulation (n = 12, p < 0.05) compared to mock or unstimulated cells (Figure 4(a)). Then, we observed that TRAIL+ NK cells were detected after overnight PBMC stimulation with recombinant IFNα (Figure 4(b)). We also observed that the cytokine had a higher capacity of inducing TRAIL in CD16− NK cells as compared to CD16+ NK cells during stimulation.

**Figure 3:** DENV-2-stimulated NK cells: subpopulation frequencies and TRAIL expression analysis. Healthy donors’ PBMCs were freshly obtained and subsequently stimulated with DENV-2 at several multiplicities of infection (10, 1, and 0.1) or negative controls as MOCK (uninfected C636 cell culture supernatant) or not stimulated (NS) for 18 hours. (a) NK cells were gated as CD3−CD56+CD16+ or CD3−CD56+CD16− and TRAIL-positive cells were detected for each subpopulation. (b) CD3−CD56+CD16− (left) or CD3−CD56+CD16+ (right) frequencies among PBMCs stimulated with MOCK (orange), DENV-2 (blue) or not stimulated (gray) are shown. (c) TRAIL-positive cells among CD3−CD56+CD16+ or CD3−CD56+CD16− after stimulation with DENV-2, MOCK, or not stimulated. Values were submitted to Friedman’s test with Dunn’s multiple comparison test in which differences with p < 0.05 (*), p < 0.005 (**) or p < 0.0005 (****) were considered statistically significant.
However, it was not possible to reproduce the high frequency of DENV-stimulated TRAIL+NK cell with recombinant IFNa, despite that higher levels of the cytokine were found in IFNα-stimulated supernatants (3309 ± 715.7 pg/mL) as compared to DENV-stimulated supernatants (1642 ± 195.8 pg/mL; n = 8; p = 0.04). Moreover, we observed that TLR3 expression on CD16– NK cells was significantly enhanced (MFI 3404± n = 3) compared to that in MOCK (MFI 2924 ± 249.4, p = 0.002) or in unstimulated cells (data not shown). Recently, we demonstrated that PDCs only express TRAIL when DENV viral particles are internalized [17]. Indeed, IFNa-stimulated PDCs were not able to express TRAIL as opposed to DENV-stimulated PDCs (Figure 4(b)). This suggests that, in opposition to PDCs, induction of TRAIL expression on NK cells may account for cytokine stimulation rather than viral particle internalization.

To further explore the role of type I interferons in TRAIL expression, we neutralized interferon alpha receptor 2 (IFNAR2) with the aid of monoclonal antibodies before viral stimulation (Figure 4(c)). Recombinant IFNα was tested to assess blocking efficiency. Treatment was efficient in blocking IFN-stimulated TRAIL expression on CD16+ NK cells (78.2% inhibition, n = 6, p < 0.05); however, IFNAR2 blocking allowed only a significant 46.5% reduction in TRAIL expression on CD16– NK cells. DENV-stimulated NK cells also presented diminished TRAIL expression when IFNAR2

---

**Figure 4: Type I interferon involvement in TRAIL expression on NK cells.** Healthy donors' PBMCs were freshly obtained and subsequently stimulated with DENV-2 at MOI 10, recombinant IFNα (150 ng/mL) or negative controls as MOCK (uninfected C636 cell culture supernatant), or not stimulated (NS) for 18 hours. Type I interferon subunit receptor 2 (IFNAR2) was blocked by treating cells with 1.5 μg/mL of IFNAR2-neutralizing antibody 30 min prior to viral stimulation. IFNa was detected in the cell culture supernatant by ELISA. (a) IFNa production by PBMC cultured with DENV-2 (blue) or MOCK (orange) in comparison with basal levels (gray). (b) Recombinant IFNa (green), mock-stimulated (orange), DENV-2-stimulated (blue), or unstimulated (grey) CD56+CD16– NK cells (left), CD56+CD16– NK cells (center) or plasmacytoid dendritic cells (PDC—right) positive for membrane TRAIL. (c) Recombinant IFNa or DENV-2-stimulated CD56+CD16– (left) or CD56+CD16+ (right) TRAIL+ NK cells treated or not with IFNAR2 neutralizing antibody. (d) Correlation between MOI 0.1 DENV-stimulated TRAIL+ NK cells (left y axis: CD16– as blue line and CD16+ as green line) or IFNa detected in supernatant (right y axis: pink) and CD14+ DENV+ monocytes among PBMCs stimulated with DENV-2 MOI10.

Values were submitted to Friedman’s test with Dunn’s multiple comparison (a) in which differences with p < 0.05 (⁎), p < 0.005 (⁎⁎) or p < 0.0005 (⁎⁎⁎) were considered statistically significant. Comparisons between two groups of data (b and c) were submitted to Wilcoxon’s matched pairs test.
was blocked. However, CD16+ NK cells are apparently more sensitive to IFNAR2 blocking than CD16− NK cells, because a reduction of 43.9% was observed in TRAIL expression of CD16+ NK cells as compared to 26.3% reduction in CD16+ NK cells. We observed that IFNAR blocking had no significant impact on IL12 levels during in vitro DENV stimulation (DENV only: median 86.17 ± 53.27 pg/mL as compared to DENV plus IFNAR: 161.58 ± 55.26 pg/mL; n = 3). Recombinant IFNa stimulation (with or without IFNAR blockage; less than 7 pg/mL; n = 3), mock stimulation (12.19 ± 3.4 pg/mL), or unstimulated (17.4 ± 2 pg/mL) had low impact on IL12 levels. Finally, we correlated the maximal dengue antigen detection on monocytes (MOI 10) among PBMC to minimal production/expression of IFNa or TRAIL+ NK cells, respectively, to observe how fast donors can respond to DENV as compared to how much DENV can replicate. Figure 4(d) demonstrates borderline significant inverse correlations concerning viral antigen detection, CD16− TRAIL+ NK cells (Pearson’s r = −0.7687, p = 0.0740), CD16+ TRAIL+ NK cells (Pearson’s r = −0.7339, p = 0.0968), and IFNa detection on supernatant of MOI 0.1 DENV-stimulated PBMCs (Spearman’s r = −0.8286, p = 0.0583). Taken together, these data account for an important but not exclusive bystander activation of NK cells by type I interferons and DENV.

4. Discussion

Dengue fever is a self-limiting febrile illness in which a life-lasting immunity is reported, even at severe cases [1]. Therefore, innate immune response deregulation may be crucial to disease outcome. Because virus loads decrease significantly over time of dengue infection, it is believed that immune response is effective in controlling viral burden, though at a cost of an enhanced inflammatory response to the host. NK cells are endowed with two effector roles: cytotoxicity towards infected cells and cytokine production, mainly IFNγ, therefore contributing to both viral clearance and inflammatory cytokine production [26].

We observed here that DENV infection influences NK cell frequencies in both subpopulations analyzed. These data are in line with our previous report [18] and also with previous publications in which a positive correlation between circulating NK cells and disease prognosis is reported [27, 28], suggesting that dengue infection has an impact on NK cell frequencies. Indeed, an initial augmentation on NK cell frequencies was also reported for other viral illnesses. For instance, yellow fever-vaccinated volunteers display enhanced frequencies of CD56+CD16+ NK cells seven days after vaccination [29]; and an early expansion followed by contraction was observed for the frequencies of NK cells from EBV-infected individuals [30]. Efficient antiviral responses rely on sufficient cell numbers, and fluctuations may reflect a higher production by bone marrow precursors, redistribution in infected tissues, or even NK cell expansion in the periphery. Indeed, IL15 levels found during acute dengue [18] may promote NK cell subset expansion. Moreover, during in vitro assays, we observed that DENV-2 stimulation could alter NK cell CD16− frequency and cytokines such as IFNa and IL12 found in supernatants. Possibly, cytokines in the milieu might act promoting cell expansion, especially on CD16− NK cells, once they are highly responsive to cytokines. Therefore, we suggest that NK cell frequencies may be correlated to protection during dengue disease.

However, NK cell numbers may not represent NK cell activation status, as it was observed for elderly individuals [30], making activation/cytotoxic phenotype an important object of analysis. We report here that CD16+ NK cell subpopulations are more likely to be activated in mild cases of dengue, when TRAIL, CD107a, and TLR3 were analyzed. Our group also reported other activation markers such as CD69 and TIA1 as upregulated in mild dengue patients [18]. However, some groups suggest that NK cell activation may have a detrimental role during dengue disease. CD69+ NK cells were correlated with severe [27] and with shock syndrome cases [31]. Despite that, recently, several genes correlated with NK cell activation were observed less abundantly in shock syndrome patients [32] and some might predict mild over severe cases [33]. Moreover, TRAIL expressed on NK cells was associated to a decreased viral load, specially during hepatitis C virus treatment with type I interferon [34] or during acute accidental HCV-controlled infection [35]. TRAIL expression seems to be important in other viral infections such as WNV and influenza murine models, in which TRAIL−/− mice fail to control viral replication [36, 37]. Taken together, these data reinforce the cytotoxic role of TRAIL during viral infections. CD107a is a marker of degranulation of cytolytic granules [23], and its expression protects NK cells against their own cytotoxicity [38]. Although CD107a was not correlated with severity, we observed it might indicate NK cell cytotoxicity towards dengue infection. Indeed, CD107a expression was correlated to NK cell activation in HCV [39], influenza [40], or HIV [41] infections. Accordingly, CD4 and CD8 T cells expressed CD107a during dengue; however, no association to severity was found [42]. Like CD107a expression, TLR3 expression was not different among dengue severity, but segregated healthy donors and mild patients. The importance of TLR3 in the induction of an antiviral response against flavivirus infections has been demonstrated. TLR3 can bind DENV antigens triggering IFNa/β antiviral responses [43, 44]. More recently, it was demonstrated that ZIKV-infected fibroblasts expressed TLR3 and TLR3 inhibition, resulting in a strong increase in viral replication [45]. Albeit a role of TLR3 in NK cells during viral infections is still elusive, yellow fever vaccination was able to enhance detection of TLR3 and TLR9 in NK cells early after vaccination [29], suggesting its role as an activation marker for NK cells. Indeed, TLR3-agonist poli I:C activation promoted in vitro CD69 expression on NK cells [46] and a low TRAIL expression [47]; viral stimulation is also able to upregulate TLR3 expression [48].

The role of IL12 during dengue infection is still elusive, however implicated in severity [49] or as a good outcome marker [50]. Regarding NK cells, not only target cells but also cytokines can activate this cell type, in which IL12 is a classic cofactor for IFNγ production [25]. Even though IFNγ plasma levels were correlated with dengue severity [11], in our work, IL12 levels were enhanced in

Mediators of Inflammation

7
mild cases. Because IL12 is involved in human NK cell cytotoxicity and alone can upregulate the activation marker NKG2D, as well as TRAIL expression on the NK cell surface [30, 31], we suggest that IL12 may have a protective role regarding this cell type.

Membrane TRAIL expression on NK cells is sufficient to promote cytotoxicity as reported elsewhere [34, 51, 52], suggesting this cytotoxic mechanism could be active also during dengue disease. DENV infection upregulates MHC I expression on infected cells [53], and dengue-specific antibody dependent cell cytotoxicity was required for in vitro NK cell-mediated cell death [54], suggesting that dengue could block NK activation. TRAIL was differentially expressed in NK cell subpopulations analyzed here, and this dichotomy may reflect different cytotoxicity features between these subsets. CD56bright (here CD56+CD16−) NK cells express very low levels of perforin and depend on TRAIL for their cytotoxicity [55]. This subset is abundant in secondary lymphoid organs (SLO) where immunoregulatory functions are observed through cytokine production [56]. TRAIL+CD56+CD16− could promote apoptosis of super stimulated or infected cells localized in SLO, diminishing inflammatory response and viral load. Moreover, because dengue-infected antigen-presenting cells migrate to SLO in theory, NK cell-response and viral load. Moreover, because dengue-infected patients produced high levels of TRAIL and IFN-α and PDC activation were productively expressed in human monocytes, suggesting NK cells might participate directly in a strong innate immune response against acute DENV infection.

These data strongly support that PDC-NK cell crosstalk during dengue would be beneficial to the host. A fast and productive type I interferon secretion by activated PDCs would enhance NK cell cytotoxicity towards infected cells, leading to a fast viral clearance. Although there are many questions about its function, we described here a small part of a possible antiviral mechanism of innate response during DENV infection that can be useful for the development of new drugs or other interventions as well as in the understanding of dengue pathogenesis.

**Conflicts of Interest**

The authors declare that there is no conflict of interest.

**Acknowledgments**

The authors thank all the health professionals from Mato Grosso do Sul, especially those working in dengue surveillance. The authors gratefully thank Dr. Ana Rita Motta Castro for their help and assistance with patient recruitment and sample collection. The authors thank the Flow Cytometry core RPT08-A of Oswaldo Cruz Foundation, especially Iris Alvim and Geraldo Pereira for their technical support. The authors gratefully acknowledge the voluntary participation of patients and healthy individuals in this study.

**References**

[1] M. G. Guzman and E. Harris, “Dengue,” *Lancet*, vol. 385, no. 9966, pp. 453–465, 2015.

[2] M. T. Fernandez-Mestre, K. Gendzekhadze, P. Rivas-Vetencourt, and Z. Layrisse, “TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients,” *Tissue Antigens*, vol. 64, no. 4, pp. 469–472, 2004.

[3] H. Loke, D. B. Bethell, C. X. Phuong et al., “Strong HLA class I–restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?,” *The Journal of Infectious Diseases*, vol. 184, no. 11, pp. 1369–1373, 2001.

[4] C. Xavier-Carvalho, G. Gibson, P. Brasil et al., “Single nucleotide polymorphisms in candidate genes and dengue severity in children: a case-control, functional and meta-analysis study,” *Infection, Genetics and Evolution*, vol. 20, pp. 197–205, 2013.

[5] J. Mongkolpapaya, W. Dejnirattisai, X. N. Xu et al., “Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever,” *Nature Medicine*, vol. 9, no. 7, pp. 921–927, 2003.

[6] S. B. Halstead, “Pathogenesis of dengue: challenges to molecular biology,” *Science*, vol. 239, no. 4839, pp. 476–481, 1988.

[7] K. C. Leitmeyer, D. W. Vaughn, D. M. Watts et al., “Dengue virus structural differences that correlate with pathogenesis,” *Journal of Virology*, vol. 73, no. 6, pp. 4738–4747, 1999.

[8] Y. H. Lee, W. Y. Leong, and A. Wilder-Smith, “Markers of dengue severity: a systematic review of cytokines and chemokines,” *The Journal of General Virology*, vol. 97, no. 12, pp. 3103–3119, 2016.
[9] A. M. Green, P. R. Beatty, A. Hadjilou, and E. Harris, “Innate immunity to dengue virus infection and subversion of antiviral responses,” *Journal of Molecular Biology*, vol. 426, no. 6, pp. 1148–1160, 2014.

[10] R. Paolini, G. Bernardini, R. Molfetta, and A. Santoni, “NK cells and interferons,” *Cytokine & Growth Factor Reviews*, vol. 26, no. 2, pp. 113–120, 2015.

[11] S. Jost and M. Altfeld, “Control of human viral infections by natural killer cells,” *Annual Review of Immunology*, vol. 31, pp. 163–194, 2013.

[12] K. Sato, S. Hida, H. Takayanagi et al., “Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta,” *European Journal of Immunology*, vol. 31, no. 11, pp. 3138–3146, 2001.

[13] L. Zamai, M. Ahmad, I. M. Bennett, L. Azzoni, E. S. Almenri, and B. Perussia, “Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells,” *The Journal of Experimental Medicine*, vol. 188, no. 12, pp. 2375–2380, 1998.

[14] S. R. Wiley, K. Schooley, P. I. Smolak et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,” *Immunity*, vol. 3, no. 6, pp. 673–682, 1995.

[15] H. Walczak, M. A. Degli-Esposti, R. S. Johnson et al., “TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL,” *The EMBO Journal*, vol. 16, no. 17, pp. 5386–5397, 1997.

[16] R. V. Warke, K. J. Martin, K. Giaya, S. K. Shaw, A. L. Rothman, and I. Bosch, “TRAIL is a novel antiviral protein against dengue virus,” *Journal of Virology*, vol. 82, no. 1, pp. 555–564, 2008.

[17] M. Gandini, C. Gras, E. L. Azeredo et al., “Dengue virus activates membrane TRAIL relocalization and IFN-alpha production by human plasmacytoid dendritic cells in vitro and in vivo,” *PLoS Neglected Tropical Diseases*, vol. 7, no. 6, article e2257, 2013.

[18] E. L. Azeredo, L. M. De Oliveira-Pinto, S. M. Zagne, D. I. Cerqueira, R. M. Nogueira, and C. F. Kubelka, “NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease,” *Clinical and Experimental Immunology*, vol. 143, no. 2, pp. 345–356, 2006.

[19] R. S. Lanciotti, C. H. Calisher, D. J. Gubler, G. J. Chang, and A. V. Vornad, “Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction,” *Journal of Clinical Microbiology*, vol. 30, no. 3, pp. 545–551, 1992.

[20] S. B. Halstead and N. J. Marchette, “Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii,” *The American Journal of Tropical Medicine and Hygiene*, vol. 69, no. 6, Supplement, pp. 5–11, 2003.

[21] WHO/TDR, *Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control—New Edition*, World Health Organization (WHO) and the Special Programme for Research and Training in Tropical Diseases (TDR), Geneva (Switzerland), 2009, http://apps.who.int/iris/bitstream/10665/44188/1/9789241547871_eng.pdf.

[22] H. Spits, D. Artis, M. Colonna et al., “Innate lymphoid cells—a proposal for uniform nomenclature,” *Nature Reviews Immunology*, vol. 13, no. 2, pp. 145–149, 2013.

[23] G. Alter, J. M. Malenfant, and M. Altfeld, “CD107a as a functional marker for the identification of natural killer cell activity,” *Journal of Immunological Methods*, vol. 294, no. 1-2, pp. 15–22, 2004.

[24] X. Y. Fu, B. Y. Yang, J. Q. Huang, X. G. Long, and C. Y. Wu, “IL-12-induced expression of TRAIL enhances the cytotoxicity of NK cells against Jurkat cells,” *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*, vol. 28, no. 9, pp. 926–929, 2012.

[25] C. Zhang, J. Zhang, J. Niu, Z. Zhou, J. Zhang, and Z. Tian, “Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D,” *Human Immunology*, vol. 69, no. 8, pp. 490–500, 2008.

[26] S. Gabrielli, C. Ortolani, G. Del Zotto et al., “The memories of NK cells: innate-adaptive immune intrinsic crosstalk,” *Journal of Immunology Research*, vol. 2016, Article ID 1376595, 14 pages, 2016.

[27] S. Green, S. Pichyangkul, D. W. Vaughn et al., “Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever,” *The Journal of Infectious Diseases*, vol. 180, no. 5, pp. 1429–1435, 1999.

[28] S. F. Wahid, S. Sanusi, M. M. Zawawi, and R. A. Ali, “A comparison of the pattern of liver involvement in dengue hemorrhagic fever with classic dengue fever,” *The Southeast Asian Journal of Tropical Medicine and Public Health*, vol. 31, no. 2, pp. 259–263, 2000.

[29] P. C. Neves, D. C. Matos, R. Marcovitz, and R. Galler, “TLR expression and NK cell activation after human yellow fever vaccination,” *Vaccine*, vol. 27, no. 41, pp. 5543–5549, 2009.

[30] Y. Zhang, D. L. Wallace, C. M. de Lara et al., “In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection,” *Immunology*, vol. 121, no. 2, pp. 258–265, 2007.

[31] T. N. Chau, N. T. Quyen, T. T. Thuy et al., “Dengue in Vietnamese infants—results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity,” *The Journal of Infectious Diseases*, vol. 198, no. 4, pp. 516–524, 2008.

[32] S. Devignot, C. Sapet, V. Duong et al., “Genome-wide expression profiling decipher host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue,” *PLoS One*, vol. 5, no. 7, article e11671, 2010.

[33] P. Sun, J. Garcia, G. Comach et al., “Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity,” *PLoS Neglected Tropical Diseases*, vol. 7, no. 7, article e2298, 2013.

[34] K. A. Stegmann, N. K. Bjorkstrom, H. Veber et al., “Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection,” *Gastroenterology*, vol. 138, no. 5, pp. 1885–1897, 2010.

[35] J. M. Werner, T. Heller, A. M. Gordon et al., “Innate immune responses in hepatitis C virus-exposed healthcare workers who do not develop acute infection,” *Hepatology*, vol. 58, no. 5, pp. 1621–1631, 2013.

[36] B. Shrestha, A. K. Pinto, S. Green, I. Bosch, and M. S. Diamond, “CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons,” *Journal of Virology*, vol. 86, no. 17, pp. 8937–8948, 2012.

[37] E. Ishikawa, M. Nakazawa, M. Yoshinari, and M. Minami, “Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice,” *Journal of Virology*, vol. 79, no. 12, pp. 7658–7663, 2005.
Mediators of Inflammation

[38] A. Cohnen, S. C. Chiang, A. Stojanovic et al., "Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage," Blood, vol. 122, no. 8, pp. 1411–1418, 2013.

[39] D. M. Hotho, K. Kreeft, Z. M. Groothuismink, H. L. Janssen, R. J. de Knegt, and A. Boonstra, "Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use," Antiviral Research, vol. 97, no. 3, pp. 347–353, 2013.

[40] J. Wang, F. Li, M. Zheng, R. Sun, H. Wei, and Z. Tian, "Lung natural killer cells in mice: phenotype and response to respiratory infection," Immunology, vol. 137, no. 1, pp. 37–47, 2012.

[41] C. Tomescu, F. M. Duh, M. A. Lanier et al., "Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users," AIDS, vol. 24, no. 14, pp. 2151–2160, 2010.

[42] L. M. de-Oliveira-Pinto, C. F. Marinho, T. F. Povoa et al., "Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue fever," PLoS Neglected Tropical Diseases, vol. 5, no. 1, article e926, 2011.

[43] Y. T. Tsai, S. Y. Chang, C. N. Lee, and C. L. Kao, "Human TLR3 recognizes dengue virus and modulates viral replication in vitro," Cellular Microbiology, vol. 11, no. 2007.

[44] A. M. Nasirudeen, H. H. Wong, P. Thien, S. Xu, K. P. Lam, and D. X. Liu, "RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection," PLoS Neglected Tropical Diseases, vol. 5, no. 1, article e38527, 2012.

[45] R. Hamel, O. Dejarnac, S. Wichit et al., "Biology of Zika virus infection in human skin cells," Journal of Virology, vol. 89, no. 17, pp. 8880–8896, 2015.

[46] K. N. Schmidt, B. Leung, M. Kwong et al., "APC-independent activation of NK cells by the toll-like receptor 3 agonist double-stranded RNA," Journal of Immunology, vol. 172, no. 1, pp. 138–143, 2004.

[47] Z. Tu, H. K. Hamalainen-Laanaya, I. N. Crispe, and M. S. Orloff, "Synergy between TLR3 and IL-18 promotes IFN-gamma dependent TRAIL expression in human liver NK cells," Cellular Immunology, vol. 271, no. 2, pp. 286–291, 2011.

[48] K. U. Saikhs, J. S. Lee, T. L. Kissner, B. Dyas, and R. G. Ulrich, "Toll-like receptor and cytokine expression patterns of CD56+ cells are similar to natural killer cells in response to infection with Venezuelan equine encephalitis virus replicons," The Journal of Infectious Diseases, vol. 188, no. 10, pp. 1562–1570, 2003.

[49] A. Rathakrishnan, S. M. Wang, Y. Hu et al., "Cytokine expression profile of dengue patients at different phases of illness," PLoS One, vol. 7, no. 12, article e52215, 2012.

[50] A. S. Pacsa, R. Agarwal, E. A. Elbushbishi, U. C. Chaturvedi, R. Nagar, and A. S. Mustafa, "Role of interleukin-12 in patients with dengue hemorrhagic fever," FEMS Immunology and Medical Microbiology, vol. 28, no. 2, pp. 151–155, 2000.

[51] D. Z. Song, Y. Liang, Q. Xiao et al., "TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro," Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology, vol. 296, no. 10, pp. 1552–1560, 2013.

[52] A. Glassner, M. Eisenhardt, B. Kramer et al., "NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKGD-dependent manner," Laboratory Investigation, vol. 92, no. 7, pp. 967–977, 2012.

[53] O. Hershkovitz, A. Zilka, A. Bar-Ilan et al., "Dengue virus replicon expressing the nonstructural proteins suffices to enhance membrane expression of HLA class I and inhibit lysis by human NK cells," Journal of Virology, vol. 82, no. 15, pp. 7666–7676, 2008.

[54] G. Garcia, M. Arango, A. B. Perez et al., "Antibodies from patients with dengue viral infection mediate cellular cytotoxicity," Journal of Clinical Virology, vol. 37, no. 1, pp. 53–57, 2006.

[55] N. Nielsen, N. Odum, B. Urso, L. L. Lanier, and P. Spee, "Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKGD2-D, LFA-1 and TRAIL and dampened via CD94/NKG2A," PLoS One, vol. 7, no. 2, article e31959, 2012.

[56] A. Poli, T. Michel, M. Therese, E. Andres, F. Hentges, and J. Zimmer, "CD56bright natural killer (NK) cells: an important NK cell subset," Immunology, vol. 126, no. 4, pp. 458–465, 2009.

[57] Z. D. Nightingale, C. Patkar, and A. L. Rothman, "Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus," Journal of Leukocyte Biology, vol. 84, no. 4, pp. 1028–1038, 2008.

[58] T. Matsuda, A. Almasan, M. Tomita et al., "Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand," The Journal of General Virology, vol. 86, Part 4, pp. 1055–1065, 2005.

[59] J. Arias, N. Valero, J. Mosquera et al., "Increased expression of cytokines, soluble cytokine receptors, soluble apoptosis ligand and apoptosis in dengue," Virology, vol. 452-453, pp. 42–51, 2014.

[60] K. L. Wong, W. Chen, T. Balakrishnan, Y. X. Toh, K. Fink, and S. C. Wong, "Susceptibility and response of human blood monocyte subsets to primary dengue virus infection," PLoS One, vol. 7, no. 5, article e36435, 2012.

[61] D. S. Lim, N. Yawata, K. J. Selva et al., "The combination of type I IFN, TNF-alpha, and cell surface receptor engagement with dendritic cells enables NK cells to overcome immune evasion by dengue virus," Journal of Immunology, vol. 193, no. 10, pp. 5065–5075, 2014.

[62] S. Varchetta, D. Mele, S. Mantovani et al., "Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection," Hepatology, vol. 56, no. 3, pp. 841–849, 2012.